688363 华熙生物
等待开盘 09-09 09:30:00
资讯
新帖
简况
华熙生物上半年营收、净利润双降 重要股东国寿成达持股比例进一步降低
GPLP · 08-31
华熙生物上半年营收、净利润双降 重要股东国寿成达持股比例进一步降低
股市必读:华熙生物中报 - 第二季度单季净利润同比下降25.91%
证券之星 · 08-31
股市必读:华熙生物中报 - 第二季度单季净利润同比下降25.91%
华熙生物(688363)披露2026年度“提质增效重回报”专项行动方案半年度评估报告,8月28日股价上涨0.56%
证券之星 · 08-28
华熙生物(688363)披露2026年度“提质增效重回报”专项行动方案半年度评估报告,8月28日股价上涨0.56%
华熙生物(688363)6月30日股东户数2.92万户,较上期减少3.77%
证券之星 · 08-28
华熙生物(688363)6月30日股东户数2.92万户,较上期减少3.77%
开源证券:给予华熙生物买入评级
证券之星 · 08-28
开源证券:给予华熙生物买入评级
华熙生物最新公告:2026年半年度净利润1.53亿元同比下降30.82%
证券之星 · 08-27
华熙生物最新公告:2026年半年度净利润1.53亿元同比下降30.82%
华熙生物:上半年净利润1.53亿元 同比下降30.82%
格隆汇 · 08-27
华熙生物:上半年净利润1.53亿元 同比下降30.82%
华熙生物自历史高点跌88% 某券商历史高位月2度喊买
中金财经 · 08-14
华熙生物自历史高点跌88% 某券商历史高位月2度喊买
每周股票复盘:华熙生物(688363)JUVELOOK获NMPA批准10月上市
证券之星 · 08-02
每周股票复盘:华熙生物(688363)JUVELOOK获NMPA批准10月上市
华熙生物获得发明专利授权:“一种具有紫外线防御作用的组合物及其应用”
证券之星 · 08-01
华熙生物获得发明专利授权:“一种具有紫外线防御作用的组合物及其应用”
华熙生物获得发明专利授权:“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”
证券之星 · 08-01
华熙生物获得发明专利授权:“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”
华熙生物:7月30日进行路演,方正证券、东方证券等多家机构参与
证券之星 · 07-30
华熙生物:7月30日进行路演,方正证券、东方证券等多家机构参与
华熙生物获得发明专利授权:“一种降低氨基酸表面活性剂的临界胶束浓度的方法”
证券之星 · 07-29
华熙生物获得发明专利授权:“一种降低氨基酸表面活性剂的临界胶束浓度的方法”
华熙生物获得发明专利授权:“一种菌体冻干保护剂及其用途”
证券之星 · 07-29
华熙生物获得发明专利授权:“一种菌体冻干保护剂及其用途”
华熙生物涨5.26%,开源证券二个月前给出“买入”评级
证券之星 · 07-22
华熙生物涨5.26%,开源证券二个月前给出“买入”评级
华熙生物涨6.08%,开源证券二个月前给出“买入”评级
证券之星 · 07-15
华熙生物涨6.08%,开源证券二个月前给出“买入”评级
每周股票复盘:华熙生物(688363)股东户数减少6.08%
证券之星 · 07-12
每周股票复盘:华熙生物(688363)股东户数减少6.08%
华熙生物“分子抗氧贴”专利获批,实现16小时长效抗氧化
金融界 · 07-08
华熙生物“分子抗氧贴”专利获批,实现16小时长效抗氧化
股市必读:华熙生物(688363)股东户数2.92万户,较上期减少6.08%
证券之星 · 07-08
股市必读:华熙生物(688363)股东户数2.92万户,较上期减少6.08%
华熙生物:截至2026年06月30日,公司股东人数为29,241户
证券之星 · 07-07
华熙生物:截至2026年06月30日,公司股东人数为29,241户
加载更多
公司概况
公司名称:
华熙生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2019-11-06
主营业务:
华熙生物科技股份有限公司的主营业务是研发、生产和销售透明质酸等生物活性物质原料产品及生物医用材料终端产品。公司的主要产品是原料产品、医疗终端产品、皮肤科学创新转化业务。报告期内,公司多款产品及技术成果获得行业认可。2026年3月,Hymagic™-GluHA熙芙宁和Hymagic™-VCHA分别获PCHi芳典奖屏障修复银奖和美白提亮银奖,2026第四届C-Beauty(中国医学美容产业链论坛)获得中国医美产业链大奖•医美注射剂与材料领军企业奖;2026年4月,FIXFLY™双A组合(UltraHA®J骨关节专用透明质酸钠+ACTIVENAG®N-乙酰氨基葡萄糖),凭借关节健康领域的突破性核心组合物创新与硬核科研实力,获得FBIFWow食品创新奖2026“最佳成分创新奖”;公司与迪巧品牌和京东健康平台合作发布NAG白皮书,首创“品牌+原料+平台”的三方联动模式。2026年5月,Hybloom™极光成功入选仅设20席的NYSCCInspirationHive创新专区,是唯一入选的中国原料;2026年6月,公司在第二十四届世界制药原料中国展(CPHIChina)荣获CPHIChina医药国际化领军企业奖。
发行价格:
47.79
{"stockData":{"symbol":"688363","market":"SH","secType":"STK","nameCN":"华熙生物","latestPrice":35.35,"timestamp":1788917215000,"preClose":35.32,"halted":0,"volume":2870,"delay":0,"changeRate":0.0008,"floatShares":482000000,"shares":482000000,"eps":0.4651,"marketStatus":"等待开盘","change":0.03,"latestTime":"09-09 09:30:00","open":35.35,"high":35.35,"low":35.35,"amount":101500,"amplitude":0,"askPrice":35.35,"askSize":19,"bidPrice":35.33,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.4651,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":7,"adr":0,"adjPreClose":35.32,"symbolType":"stock_kcb","openAndCloseTimeList":[[1788917400000,1788924600000],[1788930000000,1788937200000]],"highLimit":38.85,"lowLimit":31.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":481678242,"isCdr":false,"pbRate":2.4,"roa":"--","peRate":76.00516,"roe":"2.14%","epsLYR":0.61,"committee":-0.168831,"marketValue":17027000000,"turnoverRate":0,"status":0,"floatMarketCap":17027000000},"requestUrl":"/m/hq/s/688363","defaultTab":"news","newsList":[{"id":"2663700210","title":"华熙生物上半年营收、净利润双降 重要股东国寿成达持股比例进一步降低","url":"https://stock-news.laohu8.com/highlight/detail?id=2663700210","media":"GPLP","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663700210?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:21","pubTimestamp":1788171660,"startTime":"0","endTime":"0","summary":"8月27日晚间,华熙生物发布了2026年半年度报告。2026年上半年,华熙生物实现营业收入17.56亿元,同比减少22.32%;实现净利润1.53亿元,同比减少30.82%。这已是华熙生物自2024年起连续三年上半年营收、净利润双降。华熙生物在半年报中表示,净利润下滑主要是因为皮肤科学创新转化业务收入同比下降。在营收承压之际,华熙生物对费用端进行了调整。2026年上半年,华熙生物销售费用为5.99亿元,同比减少25.84%;研发费用为2.12亿元,同比减少8.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-31/doc-iniqfeam7944802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663874023","title":"股市必读:华熙生物中报 - 第二季度单季净利润同比下降25.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663874023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663874023?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:29","pubTimestamp":1788136149,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,华熙生物报收于36.15元,上涨0.56%,换手率0.47%,成交量2.27万手,成交额8216.72万元。业绩披露要点财务报告2026年中报显示,上半年度主营收入17.56亿元,同比下降22.32%;归母净利润1.53亿元,同比下降30.82%;扣非净利润1.29亿元,同比下降25.49%;其中第二季度单季度主营收入9.27亿元,同比下降21.64%;单季度归母净利润8813.48万元,同比下降25.91%;单季度扣非净利润7193.48万元,同比下降21.67%;负债率19.78%,投资收益2325.78万元,财务费用1637.3万元,毛利率67.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100002342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620340","title":"华熙生物(688363)披露2026年度“提质增效重回报”专项行动方案半年度评估报告,8月28日股价上涨0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662620340?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:14","pubTimestamp":1787915661,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,华熙生物报收于36.15元,较前一交易日上涨0.56%,最新总市值为174.13亿元。该股当日开盘35.99元,最高36.58元,最低35.92元,成交额达8216.72万元,换手率为0.47%。华熙生物科技股份有限公司于近日披露《2026年度“提质增效重回报”专项行动方案半年度评估报告》。公告显示,报告期内公司实现营业收入17.56亿元,同比下降22.32%;归母净利润1.53亿元,同比下降30.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800044769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066385","title":"华熙生物(688363)6月30日股东户数2.92万户,较上期减少3.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066385?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:41","pubTimestamp":1787910119,"startTime":"0","endTime":"0","summary":"证券之星消息,近日华熙生物披露,截至2026年6月30日公司股东户数为2.92万户,较5月29日减少1145.0户,减幅为3.77%。在医疗美容行业个股中,华熙生物股东户数低于行业平均水平,截至6月30日,医疗美容行业平均股东户数为3.16万户。从股价来看,2026年5月29日至2026年6月30日,华熙生物区间跌幅为2.75%,在此期间股东户数减少1145.0户,减幅为3.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800040773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051686","title":"开源证券:给予华熙生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662051686?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:13","pubTimestamp":1787897611,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司黄泽鹏,李昕恬近期对华熙生物进行研究并发布了研究报告《公司信息更新报告:短期盈利略承压,医美与新原料布局持续突破》,给予华熙生物买入评级。公司全产业链优势稳固,医美及新原料布局持续推进,估值合理,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级3家,增持评级2家。本文数据来源于开源证券股份有限公司,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800030096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704611","title":"华熙生物最新公告:2026年半年度净利润1.53亿元同比下降30.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704611","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662704611?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:35","pubTimestamp":1787830554,"startTime":"0","endTime":"0","summary":"华熙生物(688363.SH)发布2026年半年度报告,实现营业收入17.56亿元,同比下降22.32%;归属于上市公司股东的净利润1.53亿元,同比下降30.82%。业绩下降主要系皮肤科学创新转化业务收入同比下降所致。注:公司Q2净利润0.88亿,Q1净利润0.65亿,据此计算,Q2净利润环比增长36%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700046428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662018697","title":"华熙生物:上半年净利润1.53亿元 同比下降30.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662018697","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662018697?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:15","pubTimestamp":1787829347,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659411273","title":"华熙生物自历史高点跌88% 某券商历史高位月2度喊买","url":"https://stock-news.laohu8.com/highlight/detail?id=2659411273","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659411273?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:08","pubTimestamp":1786698481,"startTime":"0","endTime":"0","summary":"中国经济网北京8月14日讯 华熙生物(688363.SH)今日收报37.45元,跌幅2.90%。\r\n\r\n 2021年7月5日,华熙生物股价创下上市以来的高点314.99元。经复权,华熙生物股价较历史高点跌幅达87.81%。\r\n\r\n 国金证券股份有限公司研究员袁维2021年7月5日发布研报《华熙生物 (688363)公司点评:营收端超预期增长 功能性护肤品持续放量》称,维持“买入”评级。\r\n\r\n 国金证券股份有限公司研究员袁维2021年7月20日发布研报《华熙生物 (688363)深度报告:四轮驱动战略建立透明质酸全产业链布局》称,维持“买入”评级。\r\n\r\n (责任编辑:徐自立)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260814/32335331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688363","BK0239","BK0229","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656578316","title":"每周股票复盘:华熙生物(688363)JUVELOOK获NMPA批准10月上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2656578316","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656578316?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:42","pubTimestamp":1785606135,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,华熙生物报收于40.03元,较上周的36.33元上涨10.18%。答:2026年7月28日,公司代理的韩国VIM GLOBL聚乳酸面部填充剂JUVELOOK正式获得国家药品监督管理局批准上市。答:JUVELOOK于2014年在韩国上市,目前已进入全球60多个国家和地区,累计销量超过300万瓶,具备良好的国际市场验证基础。答:JUVELOOK获批后,国内上市准备工作已启动,产品预计于2026年10月正式上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656396235","title":"华熙生物获得发明专利授权:“一种具有紫外线防御作用的组合物及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2656396235","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656396235?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:38","pubTimestamp":1785526712,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“一种具有紫外线防御作用的组合物及其应用”,专利申请号为CN202410382572.4,授权日为2026年7月31日。今年以来华熙生物新获得专利授权38个,较去年同期减少了5%。通过天眼查大数据分析,华熙生物科技股份有限公司共对外投资了34家企业,参与招投标项目505次;财产线索方面有商标信息5505条,专利信息939条,著作权信息114条;此外企业还拥有行政许可93个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100003624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656396420","title":"华熙生物获得发明专利授权:“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2656396420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656396420?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:38","pubTimestamp":1785526703,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”,专利申请号为CN202411996519.X,授权日为2026年7月31日。专利摘要:本申请提供一种N乙酰葡萄糖胺2差向异构酶突变体和N乙酰神经氨酸裂合酶突变体及其应用。今年以来华熙生物新获得专利授权38个,较去年同期减少了5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100003594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655014876","title":"华熙生物:7月30日进行路演,方正证券、东方证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2655014876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655014876?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:01","pubTimestamp":1785409281,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年7月30日华熙生物发布公告称公司于2026年7月30日进行路演,方正证券、东方证券、国泰海通证券、申万宏源、云富投资集团有限公司参与。本次产品代理将进一步完善公司医美产品布局,但未来销售情况将受到行业政策、市场竞争、需求变化等因素影响,对公司业绩影响具有不确定性。该股最近90天内共有7家机构给出评级,买入评级5家,增持评级2家;过去90天内机构目标均价为60.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000032424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601901","BK0183","BK0028","600958","BK1147","BK0012","BK0122","BK1564","BK0276","BK0229","BK0239","03958","BK0188","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882737","title":"华熙生物获得发明专利授权:“一种降低氨基酸表面活性剂的临界胶束浓度的方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882737","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655882737?lang=zh_cn&edition=full","pubTime":"2026-07-29 03:34","pubTimestamp":1785267292,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“一种降低氨基酸表面活性剂的临界胶束浓度的方法”,专利申请号为CN202310330806.6,授权日为2026年7月28日。今年以来华熙生物新获得专利授权35个,较去年同期减少了12.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900003720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655267882","title":"华熙生物获得发明专利授权:“一种菌体冻干保护剂及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2655267882","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655267882?lang=zh_cn&edition=full","pubTime":"2026-07-29 03:32","pubTimestamp":1785267164,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“一种菌体冻干保护剂及其用途”,专利申请号为CN202211633922.7,授权日为2026年7月28日。其中,所述菌体冻干保护剂包括透明质酸或其盐和鼠李糖。今年以来华熙生物新获得专利授权35个,较去年同期减少了12.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900003184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753139","title":"华熙生物涨5.26%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653753139?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:45","pubTimestamp":1784709928,"startTime":"0","endTime":"0","summary":"今日华熙生物涨5.26%,收盘报38.8元。2026年4月24日,开源证券研究员黄泽鹏,李昕恬发布了对华熙生物的研报《公司信息更新报告:主动变革利润高增,合成生物学管线突破可期》,该研报对华熙生物给出“买入”评级。公司是玻尿酸龙头,全产业链协同发力,战略调整已卓有成效,期待后续盈利能力持续优化,估值合理,维持“买入”评级。华熙生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651453992","title":"华熙生物涨6.08%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651453992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651453992?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:22","pubTimestamp":1784103740,"startTime":"0","endTime":"0","summary":"今日华熙生物涨6.08%,收盘报36.45元。2026年4月24日,开源证券研究员黄泽鹏,李昕恬发布了对华熙生物的研报《公司信息更新报告:主动变革利润高增,合成生物学管线突破可期》,该研报对华熙生物给出“买入”评级。公司是玻尿酸龙头,全产业链协同发力,战略调整已卓有成效,期待后续盈利能力持续优化,估值合理,维持“买入”评级。华熙生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154130","title":"每周股票复盘:华熙生物(688363)股东户数减少6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650154130?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:38","pubTimestamp":1783795091,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,华熙生物报收于35.71元,较上周的37.32元下跌4.31%。本周,华熙生物7月6日盘中最高价报37.5元。股本股东变化股东户数变动截至2026年6月30日,公司股东户数为2.92万户,较5月8日减少1892.0户,减幅为6.08%。北京市通商律师事务所关于华熙生物科技股份有限公司差异化分红事项之专项法律意见书华熙生物因实施股份回购,回购专用证券账户中的3,315,538股不参与2025年度利润分配,导致总股本与实际参与分配股份数存在差异,构成差异化分红。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649975951","title":"华熙生物“分子抗氧贴”专利获批,实现16小时长效抗氧化","url":"https://stock-news.laohu8.com/highlight/detail?id=2649975951","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649975951?lang=zh_cn&edition=full","pubTime":"2026-07-08 10:02","pubTimestamp":1783476160,"startTime":"0","endTime":"0","summary":"近日,华熙生物创新研究院自主研发的“分子抗氧贴”化妆品组合物技术正式获得国家发明专利授权。抗氧化“短效失效”,消费者与品牌双重难题随着功效护肤需求持续升级,抗氧化已成为护肤核心刚需赛道。阿魏酸、麦角硫因保护率稳定超 40%,16小时仍可维持有效抗氧化浓度,可覆盖日间全时段防护需求。","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2026/07/08/0481ce2c82c60277c470c0e795c6230f.jpeg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/07/08/0481ce2c82c60277c470c0e795c6230f.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/07/08100257736567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934787","title":"股市必读:华熙生物(688363)股东户数2.92万户,较上期减少6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934787","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649934787?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:23","pubTimestamp":1783448594,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘,华熙生物报收于34.72元,下跌4.3%,换手率0.65%,成交量3.13万手,成交额1.1亿元。股本股东变化:截至2026年6月30日,股东户数为2.92万户,较5月8日减少6.08%;户均持股由1.59万股增至1.65万股。谢谢董秘: 尊敬的投资者,您好,截至2026年06月30日,公司股东人数为29,241户,感谢您的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800001268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649600834","title":"华熙生物:截至2026年06月30日,公司股东人数为29,241户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649600834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649600834?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:51","pubTimestamp":1783410694,"startTime":"0","endTime":"0","summary":"证券之星消息,华熙生物(688363)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2026年6月30日公司的股东总数是多少?谢谢华熙生物回复:尊敬的投资者,您好,截至2026年06月30日,公司股东人数为29,241户,感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700023216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788917239637,"stockEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0888},{"period":"3month","weight":0.0521},{"period":"6month","weight":-0.2083},{"period":"1year","weight":-0.4082},{"period":"ytd","weight":-0.1871}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.0457},{"period":"1year","weight":0.0297},{"period":"ytd","weight":-0.0071}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华熙生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29241人(较上一季度减少3.77%)","perCapita":"16472股","listingDate":"2019-11-06","address":"山东省济南市历下区高新技术开发区天辰大街678号","registeredCapital":"48167万元","survey":" 华熙生物科技股份有限公司的主营业务是研发、生产和销售透明质酸等生物活性物质原料产品及生物医用材料终端产品。公司的主要产品是原料产品、医疗终端产品、皮肤科学创新转化业务。报告期内,公司多款产品及技术成果获得行业认可。2026年3月,Hymagic™-GluHA熙芙宁和Hymagic™-VCHA分别获PCHi芳典奖屏障修复银奖和美白提亮银奖,2026第四届C-Beauty(中国医学美容产业链论坛)获得中国医美产业链大奖•医美注射剂与材料领军企业奖;2026年4月,FIXFLY™双A组合(UltraHA®J骨关节专用透明质酸钠+ACTIVENAG®N-乙酰氨基葡萄糖),凭借关节健康领域的突破性核心组合物创新与硬核科研实力,获得FBIFWow食品创新奖2026“最佳成分创新奖”;公司与迪巧品牌和京东健康平台合作发布NAG白皮书,首创“品牌+原料+平台”的三方联动模式。2026年5月,Hybloom™极光成功入选仅设20席的NYSCCInspirationHive创新专区,是唯一入选的中国原料;2026年6月,公司在第二十四届世界制药原料中国展(CPHIChina)荣获CPHIChina医药国际化领军企业奖。","listedPrice":47.79},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华熙生物,688363,华熙生物股票,华熙生物股票老虎,华熙生物股票老虎国际,华熙生物行情,华熙生物股票行情,华熙生物股价,华熙生物股市,华熙生物股票价格,华熙生物股票交易,华熙生物股票购买,华熙生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}